Pulmonx (LUNG) Projected to Post Quarterly Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is projected to announce its earnings results after the market closes on Wednesday, February 19th. Analysts expect the company to announce earnings of ($0.45) per share and revenue of $22.29 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Pulmonx Stock Down 5.6 %

LUNG stock opened at $6.97 on Tuesday. Pulmonx has a twelve month low of $5.46 and a twelve month high of $14.84. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The firm has a market cap of $275.25 million, a PE ratio of -4.74 and a beta of 0.64. The business has a 50 day moving average of $6.41 and a 200 day moving average of $6.74.

Insider Buying and Selling at Pulmonx

In other news, Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $6.63, for a total value of $132,600.00. Following the sale, the director now directly owns 1,071,974 shares of the company’s stock, valued at approximately $7,107,187.62. The trade was a 1.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel David Aaron Lehman sold 5,497 shares of Pulmonx stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.19, for a total value of $34,026.43. Following the completion of the sale, the general counsel now directly owns 197,851 shares in the company, valued at $1,224,697.69. This trade represents a 2.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,199 shares of company stock valued at $208,859 over the last ninety days. 5.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have commented on the company. Wells Fargo & Company cut their target price on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Stifel Nicolaus cut their target price on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Finally, Citigroup reiterated a “neutral” rating and set a $7.50 target price (down from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.75.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.